T1	Entity 167 189	amyloid-β (Aβ) peptide
T2	KeyEntity 199 230	amyloid precursor protein (APP)
T3	Entity 396 401	brain
T5	Entity 520 534	damaged tissue
T7	Entity 879 889	mutant APP
T8	Entity 929 940	doxycycline
T9	Entity 992 995	APP
T10	Entity 1012 1039	fulminant amyloid pathology
T11	KeyEntity 1054 1065	doxycycline
T12	KeyEntity 1090 1115	transgenic APP expression
T13	Entity 1148 1161	Aβ production
T14	Entity 1201 1239	Suppression of transgenic Aβ synthesis
T15	Entity 1273 1305	progression of amyloid pathology
T6	KeyEntity 375 388	Aβ production
R1	regulates Arg1:T6 Arg2:T5	
R2	is_part_of Arg1:T1 Arg2:T2	
R3	participates_in Arg1:T6 Arg2:T3	
T4	Entity 550 565	amyloid lesions
R4	regulates Arg1:T6 Arg2:T4	
T20	Entity 730 752	transgenic mouse model
T21	Entity 781 804	arrest of Aβ production
R5	participates_in Arg1:T20 Arg2:T21	
T22	Entity 862 866	mice
R6	other_relation Arg1:T22 Arg2:T7	
#1	AnnotatorNotes R6	overexpress
R7	regulates Arg1:T8 Arg2:T7	
R8	participates_in Arg1:T9 Arg2:T10	
R9	regulates Arg1:T11 Arg2:T12	
R10	regulates Arg1:T11 Arg2:T13	
R11	regulates Arg1:T14 Arg2:T15	
T18	Entity 1460 1557	Mice in which APP synthesis was suppressed for as long as 6 mo after the formation of Aβ deposits
T19	Entity 1580 1592	amyloid load
R12	participates_in Arg1:T18 Arg2:T19	
T16	Entity 132 141	proteases
T17	Entity 303 335	treatments for Alzheimer disease
R14	is_part_of Arg1:T16 Arg2:T17	
T23	Entity 834 854	secretase inhibitors
R15	participates_in Arg1:T23 Arg2:T21	
T24	Entity 143 153	secretases
R16	is_subtype_of Arg1:T24 Arg2:T16	
R13	regulates Arg1:T24 Arg2:T2	
R17	is_subtype_of Arg1:T8 Arg2:T23	
T25	Entity 1403 1410	plaques
R18	is_subtype_of Arg1:T25 Arg2:T10	
